Recognition is growing faster than the systems built to assess it

Australian waits, costs and workforce constraints, dated. Demand is not prevalence. Old inquiry figures are not current measurements.

7 minute readEvidence last reviewed: 2 September 2026

The 2023 Senate inquiry into ADHD assessment and support heard 700 submissions and 79 witnesses. It described long waits, high costs, a thin public adult pathway, and regional gaps. Those findings are historical inquiry evidence. They are not a 2026 waiting-time figure.

Claim

1 · Statement
In Australia, ADHD assessment is constrained by clinician availability, waiting time, out-of-pocket cost, a thin public adult pathway, and regional gaps. Recognition is growing faster than the systems built to assess it.
2 · Classification
Associated. 2023 Senate inquiry (historical) plus a 2024 secret-shopper measurement published in 2026. Both describe barriers; they do not report the same numbers. Western Australia’s GP-led ADHD program (page last reviewed 31 August 2026) is a later jurisdictional change, not a national one.
3 · Papers
4 · Claim limitation
Wait-time figures age quickly. Historical inquiry testimony must not be presented as current. Quoted fees are not final out-of-pocket costs. From 31 August 2026, specially trained GPs in Western Australia can assess, diagnose and treat suitable ADHD patients aged 10+; complex presentations still go to specialists. 2024 telephone measurements do not describe that pathway.
Last reviewed
2 September 2026

A national secret-shopper study telephoned 736 clinicians between May and August 2024. Fifty-nine percent responded; about half of respondents could book an ADHD assessment. Mean waits were 7 weeks with psychologists, 16 with psychiatrists, 31 with paediatricians. Quoted total costs were often more than a thousand dollars, before rebates. Publication was February 2026. Access can have moved since the phones were called.

Claim

1 · Statement
Rising ADHD diagnosis and medicine dispensing in Australia are evidence of rising recognised demand. They are not, by themselves, evidence that underlying ADHD prevalence has increased by the same factor. Prevalence, recognition, diagnosis and service demand are different quantities.
2 · Classification
Established. Follows directly from how PBS and waitlist data are constructed. A 2025 systematic review of 40 studies across 17 countries found that the highest-quality evidence did not indicate an increase in underlying ADHD prevalence since 2020.
3 · Papers
4 · Claim limitation
True underlying prevalence over time in Australia is not cleanly measured. Over-identification and under-identification can coexist. Martin et al. (2025) themselves report substantial limitations in the prevalence literature: only four included studies were at low risk of bias; reporting delays, missing healthcare data and missing school-level data all apply.
Where evidence disagrees
Administrative diagnosis and PBS dispensing have risen sharply in Australia, especially after 2018–19 (AIHW, 2025). Some public commentary treats that rise as a rise in the underlying condition. Martin et al. (2025) found no significant rise in ADHD prevalence across 40 studies in 17 countries, and that the highest-quality findings did not suggest an increase since 2020, while incidence showed some variability during COVID-19. Rising recognition, rising demand, and rising treated numbers can all be true without a demonstrated surge in underlying prevalence.
- Australian Institute of Health and Welfare (2025). AIHW mental health data
- Martin AF (2025). Journal of Affective Disorders
Last reviewed
2 September 2026

PBS dispensing of ADHD medicines rose from 2 patients per 1,000 in 2004–05 to 22 per 1,000 in 2023–24. That is treated demand. It is not a census of how many people have ADHD. A 2025 systematic review of 40 studies across 17 countries found that the highest-quality evidence did not indicate an increase in underlying ADHD prevalence since 2020. Do not claim that underlying prevalence has necessarily increased merely because diagnostic demand has.

Claim

1 · Statement
More people being recognised is observable. More people seeking assessment is observable. More people receiving ADHD medication is observable. A sudden increase in the underlying prevalence of ADHD since 2020 is not currently established.
2 · Classification
Associated. Martin et al. (2025): forty studies, 17 countries; highest-quality findings did not suggest an increase in prevalence since 2020. Australian PBS dispensing (AIHW 2025) documents treated demand, not underlying prevalence.
3 · Papers
4 · Claim limitation
Substantial limitations in the prevalence literature. Only four included studies were at low risk of bias. Reporting delays, missing healthcare data and missing school-level data. This is not an Australian census, and it does not prove prevalence is static.
Where evidence disagrees
Clinic, education and social-media observers see more ADHD. Dispensing data confirm more treated patients. Those observations are real. They answer a different question from ‘has the underlying condition become more common?’ The honest position is the one that refuses both extremes: it is not established that ADHD is newly invented, and it is not established that underlying prevalence has suddenly surged.
Last reviewed
2 September 2026

The system changed while we were building the page

Historically, ADHD assessment and stimulant treatment in Australia have relied heavily on psychiatrists and paediatricians. As of 31 August 2026, Western Australia has formally launched a GP ADHD program: specially trained GPs can assess, diagnose and treat suitable patients from age 10, while complex presentations continue to require specialist involvement. This site recorded that change on 2 September 2026. A national picture that still says ‘see a specialist’ is already out of date in one state.

Claim

1 · Statement
Historically, ADHD assessment and stimulant treatment in Australia have relied heavily on psychiatrists and paediatricians. Pathways are now changing in some jurisdictions. In Western Australia, specially trained GPs can now assess, diagnose and treat suitable ADHD patients from age 10, while complex presentations continue to require specialist involvement.
2 · Classification
Established. WA Health program page last reviewed 31 August 2026. This is a documented jurisdictional pathway, not an inference from wait-time studies.
3 · Papers
- WA Health (2026). Government of Western Australia, Department of Health
4 · Claim limitation
Western Australia only. Age 10 and over. Suitable, not complex, presentations. Training, legislative and governance requirements still apply. This does not dissolve national access barriers, and it is not an evaluation of diagnostic quality.
Last reviewed
2 September 2026

Open the queue

Sources used on this page

Paradoxical.life provides evidence and self-documentation tools, not medical advice. If you have concerns about your health, medication or mental state, speak with a qualified medical practitioner.